Immune cells take on deadly childhood brain cancer
NCT ID NCT04196413
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether a new immune cell therapy called GD2 CAR T cells can be safely made and given to children and adults with a rare, aggressive brain tumor called H3K27M-mutant diffuse midline glioma. The study aims to find the right dose and check for side effects. Up to 97 participants will receive the treatment along with chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GD2 CAR T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for a rare and aggressive brain tumor that currently has no cure.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not yet proven to work. The treatment may cause serious side effects, and it is unclear if it will shrink tumors or extend life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA OF BRAINSTEM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lucile Packard Children's Hospital (LPCH)
RECRUITINGStanford, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.